Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hoshi Iryo-Sanki CoTSE:7634 75 Debt-to-EBITDA is 0.21 as of Mar. 2026, which is 52% below its 10-year median of 0.44. GuruFocus rates TSE:7634 with a GF Score™ of 75/100 and a GF Value™ of 円4,735.26 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 91 Medical Distribution companies, Hoshi Iryo-Sanki Co ranks better than 83.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hoshi Iryo-Sanki Co's Debt-to-EBITDA or its related term are showing as below:
TSE:7634'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28 Med: 0.44 Max: 0.54
Current: 0.43
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hoshi Iryo-Sanki Co was 0.54. The lowest was 0.28. And the median was 0.44.
TSE:7634's Debt-to-EBITDA is ranked better than 83.52% of 91
companies
in the Medical Distribution industry
Industry Median: 2.32
vs TSE:7634: 0.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hoshi Iryo-Sanki Co Debt-to-EBITDA Related Terms
Hoshi Iryo-Sanki Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hoshi Iryo-Sanki Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7634 vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Hoshi Iryo-Sanki Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoshi Iryo-Sanki Co Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hoshi Iryo-Sanki Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hoshi Iryo-Sanki Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Hoshi Iryo-Sanki Co (TSE:7634) has a Debt-to-EBITDA of 0.21 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hoshi Iryo-Sanki Co. This is 52% below median its historical median of 0.44. Over the past decade, Hoshi Iryo-Sanki Co's Debt-to-EBITDA has ranged from 0.28 to 0.54. According to the industry distribution chart, Hoshi Iryo-Sanki Co ranks #15 out of 91 companies in the Medical Distribution industry, placing it in the top 16.5%.
Is Hoshi Iryo-Sanki Co's Debt-to-EBITDA too high?
Hoshi Iryo-Sanki Co's current Debt-to-EBITDA of 0.21 is 52% below median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.54. The Medical Distribution industry median Debt-to-EBITDA is 2.32. Hoshi Iryo-Sanki Co's value of 0.21 is 90.9% below this industry median. Based on the distribution chart, Hoshi Iryo-Sanki Co ranks #15 out of 91 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hoshi Iryo-Sanki Co has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hoshi Iryo-Sanki Co's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hoshi Iryo-Sanki Co ranks #15 out of 91 companies for Debt-to-EBITDA. This places Hoshi Iryo-Sanki Co in the top 17% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.32. Hoshi Iryo-Sanki Co's value of 0.21 is 90.9% below this benchmark. Historically, Hoshi Iryo-Sanki Co's own Debt-to-EBITDA has ranged from 0.28 to 0.54 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 2.32, Hoshi Iryo-Sanki Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.32, based on 91 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hoshi Iryo-Sanki Co's current Debt-to-EBITDA of 0.21 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hoshi Iryo-Sanki Co. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hoshi Iryo-Sanki Co's current Debt-to-EBITDA is 0.21, which is 52% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hoshi Iryo-Sanki Co stock overvalued right now?
Based on GuruFocus' analysis, Hoshi Iryo-Sanki Co (TSE:7634) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,735.26, compared to a current price of 円5,270.00 — trading 11.3% above its estimated fair value. The current Debt-to-EBITDA is 0.21, which is 52% below median its 10-year median of 0.44 and 90.9% below the Medical Distribution industry median of 2.32. Hoshi Iryo-Sanki Co's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hoshi Iryo-Sanki Co (TSE:7634), the current Debt-to-EBITDA is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hoshi Iryo-Sanki Co (TSE:7634) Overvalued in 2026?
Based on GuruFocus' analysis, Hoshi Iryo-Sanki Co stock appears to be overvalued.
The current stock price of 円5,270.00 is trading 11.3% above its estimated GF Value™ of 円4,735.26.
GuruFocus considers Hoshi Iryo-Sanki Co to be Modestly Overvalued.
Key valuation signals for TSE:7634:
Debt-to-EBITDA: 0.21 (52% below median its 10-year median of 0.44)
GF Value™: 円4,735.26 vs. price of 円5,270.00 (11.3% above fair value)
Industry Position: 90.9% below the Medical Distribution median (#15 of 91)
No single metric tells the full story. See the TSE:7634 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hoshi Iryo-Sanki Co Ltd is engaged in the manufacturing and sale of pharmaceutical products. The company offers medical oxygen, nitrous oxide, and others. It is also engaged in the planning, manufacture, sale, maintenance, inspection, and repair of medical instrument equipment for medical gas supply facilities. The company's project service includes the production and supply of medical gas, home care, medical gas maintenance, and others.
75GF Score
Get the complete analysis for TSE:7634
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7634 has been successfully added to your 
